Teva's IL-15 antibody shows phase 2a promise in celiac disease
Teva's anti-IL-15 antibody TEV '408 beat placebo in a phase 2a celiac trial, reducing gluten-induced intestinal damage in 50 adults with no safety signals, paving the way for phase 3 pending further analysis; the program also spans vitiligo, with broader IL-15–axis potential in autoimmune diseases.